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Allogeneic red blood cell adsorption for 
removal of warm autoantibody
C. Barron
Adsorption studies are usually required to confirm or rule out 
the presence of underlying alloantibodies in samples containing 
warm autoantibody. Allogeneic adsorptions are necessary if the 
patient has been recently transfused. Most commonly, allogeneic 
adsorptions are performed using a trio of phenotyped reagent 
red blood cells to rule out clinically significant alloantibodies to 
common antigens. The adsorbing cells may be used untreated 
or treated with enzymes or with ZZAP before adsorption. 
Adsorption may also be performed using enhancement such 
as low-ionic strength saline or polyethylene glycol added to 
the mixture. Multiple adsorptions may be necessary to remove 
strongly reactive autoantibodies. Allogeneic adsorptions 
will not detect alloantibodies to high-prevalence antigens. 
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The serum from patients with warm autoimmune 
hemolytic anemia (WAIHA) typically demonstrates broad 
reactivity with all reagent red blood cells (RBCs). This 
reactivity usually necessitates the use of incompatible blood for 
transfusion. When blood is incompatible as a result of an RBC 
autoantibody, transfused RBCs will survive at a rate similar 
to that of the patient’s own RBCs.1 However, autoantibody 
reactivity may mask the reactions of underlying clinically 
significant alloantibodies to common antigens, which can 
cause rapid RBC destruction. The rate of alloimmunization in 
patients with warm autoantibodies varies among investigators. 
Reported alloimmunization rates range from 17.5 to 38 percent, 
with an average rate of 32 percent.2–7 Issitt et al.4 found that 
47 percent of alloantibody specificities identified after 
adsorption were actually partially adsorbed autoantibodies 
with mimicking specificities. Mimicking autoantibody 
specificities were found most often when autologous adsorption 
was used to remove autoantibody reactivity. Identification of 
alloantibody specificities underlying a warm autoantibody is 
critical for a safe and effective transfusion.
Methods used to determine the presence of an alloantibody 
underlying an autoantibody include serum dilution, autologous 
adsorption, and allogeneic adsorption. The dilution screening 
method uses a 1:5 dilution of serum in phosphate-buffered 
saline. The diluted serum is tested to determine whether the 
autoantibody has been removed and whether alloantibody 
is present.8 Although this may be useful as a screening tool, 
this method has been shown to be unreliable in consistently 
detecting alloantibody underlying autoantibody.9 Autologous 
adsorption, which uses the patient’s own RBCs to remove 
the autoantibody, is a preferred method. Using autologous 
RBCs ensures that only autoantibodies are removed from the 
serum, leaving intact any alloantibody the patient may have 
produced, including antibodies to high-prevalence antigens. 
However, autologous adsorptions may only be performed 
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Ficin • 1% ficin
ZZAP • 1% cysteine-activated 
papain or 1% ficin
• 0.2 M DTT
• Commercial LISS 
enhancement reagent
• 20% PEG or commercial 
PEG enhancement
DTT = dithiothreitol; RBCs = red blood cells; LISS = low-ionic-strength 
saline; PEG = polyethylene glycol.
Procedural Steps
Preparation of RBCs for adsorption
• Select reagent RBCs for use as adsorbing cells.
• Treat the adsorbing cells with the desired enzyme or ZZAP.
Adsorption
• Add 1 to 2 volumes of treated adsorbing cells to 1 volume of 
patient serum or plasma and 1 volume of enhancement reagent (if 
applicable).
• Incubate for 30–60 minutes at 37°C without enhancement, or 15 
minutes at 37°C with LISS or PEG enhancement.
• Harvest the adsorbed serum or plasma and test for the presence of 
underlying alloantibodies.
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commonly defined as having no transfusions or pregnancy in 
the prior 3 months. Alloantibody may be removed from the 
test system if autologous adsorptions are performed using 
a sample from a recently transfused patient. Laine et al.10 
showed that even small amounts of transfused RBCs are 
capable of removing all alloantibody reactivity. Allogeneic 
RBC adsorption is the method of choice for removal of warm 
autoantibody reactivity in patients with recent transfusions. 
Note that the term “serum” is used to denote the patient sample 
throughout this article; however, either serum or plasma may 
be used for testing.
Principle
Allogeneic adsorptions are used to remove broadly reactive 
autoantibody from a patient’s serum to allow for detection of 
underlying clinically significant alloantibodies to common 
antigens. The adsorbing cells will remove autoantibody along 
with any additional antibody specificities to antigens that are 
present on the RBC. When performing allogeneic adsorptions, 
the goal is to eliminate or confirm the presence of those 
alloantibodies directed at the common antigens D, C, E, c, e, 
K, S, s, Fya, Fyb, Jka, and Jkb.
Traditional allogeneic adsorptions use a set of three 
adsorbing cells with known phenotypes: R1R1, R2R2, and rr. 
At least one of the adsorbing cells should be negative for K and 
Jka or Jkb. In addition, at least one of the reagent cells should 
also lack S or s and Fya or Fyb unless the cells are pretreated 
to denature the antigens. A separate aliquot of patient serum 
is incubated with each adsorbing cell. Once all autoantibody 
reactivity is removed, the three adsorbed serums are tested to 
eliminate or prove the presence of any underlying alloantibody. 
Each aliquot of adsorbed serum contains alloantibody 
corresponding to those antigens for which the adsorbing cell 
was negative.
If a patient’s RBC phenotype is known, it may be possible 
to adsorb using a single phenotypically similar reagent RBC. 
For instance, if a patient is only negative for E, K, S, and Fya, 
one reagent RBC negative for those antigens can be used for 
adsorption. After adsorption, the adsorbed serum can be 
tested to confirm or eliminate the presence of anti-E, -K, -S, 
and/or -Fya.
Various methods are used for performing the adsorption. 
Treatment of the adsorbing cells using enzymes or ZZAP may 
enhance the uptake of the autoantibody.9 These cell treat- 
ments will also destroy some antigens, which may be 
advantageous when selecting cells for adsorption and testing 
the adsorbed serum. Rarely, autoantibodies may demonstrate 
specificity corresponding to an antigen that is destroyed by 
enzymes (e.g., anti-Ge2) or ZZAP (e.g., anti-LWa or Kell system 
antibodies). In these cases, adsorption with untreated reagent 
RBCs is necessary.
The addition of enhancement media to the adsorbing 
mixture has also become commonplace and can be used in 
place of RBC pretreatment. The addition of low-ionic-strength 
saline (LISS) or polyethylene glycol (PEG) reduces the 
processing time and may decrease the number of adsorptions 
required to remove the autoantibody.9,11,12 However, some 
investigators caution that some underlying alloantibodies may 
not be detected when PEG adsorptions are performed.13,14
Indications
Allogeneic adsorptions should be used when a patient has 
been recently transfused or when autologous cells are of limited 
supply. Adsorption eliminates the reactivity of the warm 
autoantibody, allowing for the identification of alloantibodies 
in the adsorbed serum.
Procedure
Select cells for adsorption. If the patient’s RBC phenotype is 
known, select a phenotypically similar reagent RBC that lacks 
the same common RBC antigens as the patient’s RBCs. If the 
patient’s RBC phenotype is unknown, select a trio of reagent 
RBCs: R1R1, R2R2, and rr. Additionally, at least one cell of the 
set should be negative for K and Jka or Jkb so that all common 
alloantibodies can be detected using the adsorbed serum. If 
adsorptions will be performed using untreated reagent RBCs, 
at least one cell should be negative for S or s and Fya or Fyb as 
well.15–18
If desired, treat the adsorbing cells with enzymes (ficin 
or papain) or ZZAP (ficin or papain and 0.2 M DTT). This 
pretreatment will typically enhance the adsorbing process.
Following pretreatment, wash the adsorbing cells, 
centrifuge, and remove all excess saline before use. Perform 
the adsorption by mixing one to two volumes of allogeneic 
RBCs with one volume of patient serum at 37°C for 30 to 60 
minutes. 
Another option is to perform the adsorption by mixing 
one volume of patient serum and one volume of LISS or PEG19 
with one to two volumes of allogeneic reagent RBCs at 37°C 
for 15 minutes.15–18
After the adsorption, centrifuge the mixture and harvest 
the adsorbed serum. Test the adsorbed serum to determine 
whether adsorption is complete. This may be accomplished 
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by testing the adsorbed serum against the adsorbing cells 
or by testing the adsorbed serum against a reagent RBC 
phenotypically similar to the adsorbing cell. If necessary, 
repeat the adsorption using a new aliquot of adsorbing cells.
Once adsorption is complete, test the adsorbed serum 
against reagent RBCs to rule out the presence of underlying 
alloantibodies. For instance, if the adsorbing cell is R1R1, S–, 
K– Jk(a–), then the following alloantibodies can be ruled out 
in that aliquot of adsorbed serum; anti-E, -c, -S, -K, and -Jka. 
Note: Test the adsorbed serum from the LISS or PEG 
enhancements using four drops of the serum/enhancement 
reagent mixture.
Limitations
Allogeneic adsorption will not rule out the presence of 
alloantibodies to high-prevalence antigens. The adsorbing cells 
are presumed to be positive for all high-prevalence antigens; 
therefore, an alloantibody to a high-prevalence antigen would 
be adsorbed along with the autoantibody.
When a patient’s serum contains a very potent warm 
autoantibody, multiple adsorptions are needed to remove the 
broad reactivity. Generally, for each grade of reactivity, at least 
one adsorption will be necessary (a serum sample with an 
autoantibody that reacts 2+ will require a minimum of two 
adsorptions). Multiple adsorptions have the potential to dilute 
the serum. Increasing the ratio of adsorbing cells to serum 
may enhance the removal of the autoantibody.
The use of PEG adsorption may cause weakening or loss 
of antibody reactivity in some samples. The use of six drops of 
the serum/PEG mixture in antibody identification tests may 
minimize this effect.
Quality Control
To determine whether the adsorbing cells are adequately 
treated with enzymes, test the cells with Glycine max var. soja 
lectin. Enzyme-treated RBCs should demonstrate positive 
reactivity with G. max var. soja and untreated RBCs should 
be nonreactive.
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